Pfizer and Anumana boost detection of cardiovascular disease

Related Articles
Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection
Medtech Dive: Anumana, a health technology startup spun out of Mayo Clinic, entered a multi-year agreement with Pfizer to develop an algorithm to detect cardiac amyloidosis, a serious heart condition.…December 16, 2022
Anumana Appoints Kevin Ballinger and Jean-Luc Butel to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana Inc., a leader in AI-powered cardiovascular detection algorithms, today announced the appointment of Kevin Ballinger and Jean-Luc Butel to its Board of Directors. In their roles, Ballinger and…January 12, 2026
How Doctors Use AI to Help Diagnose Patients
Wall Street Journal: At Mayo cardiology, an AI tool has helped doctors diagnose new cases of heart failure and cases of irregular heart rhythms, which are called atrial fibrillation, potentially…February 28, 2023
Anumana Collaborates with Novartis Pharmaceuticals Corporation
AI TechPark: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of…July 13, 2022


